HC Wainwright Issues Positive Forecast for Septerna (NASDAQ:SEPN) Stock Price

Septerna (NASDAQ:SEPN) had its price target upped by HC Wainwright from $26.00 to $30.00 in a research note published on Tuesday,Benzinga reports. They currently have a buy rating on the stock.

Several other research analysts have also issued reports on SEPN. Cantor Fitzgerald reiterated an “overweight” rating and issued a $25.00 price target on shares of Septerna in a report on Friday, September 5th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Septerna in a research report on Wednesday, October 8th. Finally, Wall Street Zen cut Septerna from a “hold” rating to a “sell” rating in a report on Saturday. Four analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $27.75.

Septerna Trading Up 6.3%

SEPN stock opened at $19.24 on Tuesday. Septerna has a 1-year low of $4.17 and a 1-year high of $28.99. The stock has a 50-day moving average price of $18.96 and a 200-day moving average price of $13.57. The firm has a market cap of $857.72 million and a PE ratio of -12.74.

Septerna (NASDAQ:SEPN) last posted its quarterly earnings results on Monday, November 10th. The company reported ($0.09) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.19 by ($0.28). The business had revenue of $21.50 million for the quarter, compared to the consensus estimate of $24.50 million. Septerna had a negative return on equity of 17.86% and a negative net margin of 266.77%. On average, analysts forecast that Septerna will post -7.11 earnings per share for the current year.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the company. BVF Inc. IL grew its position in Septerna by 79.3% in the 1st quarter. BVF Inc. IL now owns 4,396,124 shares of the company’s stock worth $25,454,000 after purchasing an additional 1,944,100 shares in the last quarter. TRV GP VI LLC boosted its stake in shares of Septerna by 33.6% in the 1st quarter. TRV GP VI LLC now owns 4,211,659 shares of the company’s stock worth $24,386,000 after buying an additional 1,059,203 shares during the last quarter. Driehaus Capital Management LLC boosted its stake in shares of Septerna by 20.6% in the 1st quarter. Driehaus Capital Management LLC now owns 3,122,608 shares of the company’s stock worth $18,080,000 after buying an additional 533,055 shares during the last quarter. Vanguard Group Inc. grew its holdings in shares of Septerna by 7.4% in the third quarter. Vanguard Group Inc. now owns 1,518,757 shares of the company’s stock valued at $28,568,000 after acquiring an additional 104,394 shares in the last quarter. Finally, Checkpoint Capital L.P. purchased a new stake in shares of Septerna during the first quarter valued at approximately $4,776,000.

About Septerna

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases.